-
公开(公告)号：US20230019236A1
公开(公告)日：2023-01-19
申请号：US17807292
申请日：2022-06-16
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Elliot P. Farney , Reza Shiroodi , Zhaoming Xiong , Qingwei Zhang , Matthew J. O'Connor , Geoff T. Halvorsen , Hongyu Zhao , Christina Baumgartner , Jennifer M. Frost , Philip R. Kym , Jason R. Abbott , Andrew Bogdan , Christos Economou , Xueqing Wang
IPC: A61K31/433 , A61K39/395 , A61P35/00 , C07D417/10 , A61K31/5377 , C07D285/06
Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
-
公开(公告)号：US10954202B2
公开(公告)日：2021-03-23
申请号：US17025644
申请日：2020-09-18
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Zhaoming Xiong , Jennifer M. Frost , Philip R. Kym , Xueqing Wang , Shuang Chen , Dennie Welch
IPC: C07D285/10
Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
-
Patent Agency Ranking
公开(公告)号：US20210009542A1
公开(公告)日：2021-01-14
申请号：US17025644
申请日：2020-09-18
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Zhaoming Xiong , Jennifer M. Frost , Philip R. Kym , Xueqing Wang , Shuang Chen , Dennie Welch
IPC: C07D285/10
Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
-
公开(公告)号：US20160122331A1
公开(公告)日：2016-05-05
申请号：US14926727
申请日：2015-10-29
Applicant: AbbVie Inc.
Inventor： Philip R. Kym , Xueqing Wang , Xenia B. Searle , Bo Liu , Ming C. Yeung
IPC: C07D407/12 , A61K45/06 , A61K31/357
CPC classification number: C07D407/12 , A61K31/357 , A61K45/06
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts or radiolabelled forms thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and m are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
Abstract translation: 式（I）化合物及其药学上可接受的盐或放射性标记形式，其中R1，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，R12和m如说明书中所定义，是有用的 在治疗由囊性纤维化跨膜电导调节剂（CFTR）蛋白质预防或改善的病症或障碍。 描述了制备化合物的方法。 还描述了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。
-
公开(公告)号：US20160120841A1
公开(公告)日：2016-05-05
申请号：US14925649
申请日：2015-10-28
Applicant: AbbVie Inc.
Inventor： Philip R. Kym , Xueqing Wang , Xenia B. Searle , Bo Liu , Ming C. Yeung , Robert J. Altenbach , Eric Voight , Andrew Bogdan , John R. Koenig
IPC: A61K31/353 , A61K45/06 , C07D405/14 , A61K31/4433 , C07D491/052 , A61K31/435 , A61K31/4025 , A61K31/453 , C07D413/14 , A61K31/5377 , A61K31/397 , C07D491/107 , C07D407/12 , A61K31/436
CPC classification number: C07D407/12 , A61K31/00 , A61K31/353 , A61K31/397 , A61K31/4025 , A61K31/435 , A61K31/436 , A61K31/4433 , A61K31/453 , A61K31/5377 , A61K45/06 , C07D405/14 , C07D413/14 , C07D491/052 , C07D491/107 , A61K2300/00
Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
Abstract translation: 本发明提供式（I）化合物，其中R1，X，Y，R4，R5，R6，R7，R8，R9，R10，R11，R12，R13，R14，m和R“具有定义的任何值 在本说明书及其药学上可接受的盐中，其可用作治疗由CFTR介导和调节的疾病和病症的药剂，包括囊性纤维化，Siegren综合征，胰腺功能不全，慢性阻塞性肺病和慢性阻塞性气道疾病。 还提供了由一种或多种式（I）化合物组成的药物组合物。
-
公开(公告)号：US08906911B2
公开(公告)日：2014-12-09
申请号：US13853394
申请日：2013-03-29
Applicant: AbbVie Inc.
Inventor： Michael D. Meyer , Xueqing Wang , Tao Guo , Robert Guo Ping Wei , Lijuan Jane Wang
IPC: C07D487/04 , C07D487/08 , A61K31/427 , A61K31/407 , A61K31/4439 , A61K31/501 , A61K31/506 , A61K31/4995 , A61K31/5377 , C07D451/02
CPC classification number: C07D487/08 , C07D451/02
Abstract: Disclosed herein are chemokine receptor antagonists of formula (I) wherein R1, R2, and R3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.
Abstract translation: 本文公开了式（I）的趋化因子受体拮抗剂，其中R 1，R 2和R 3如说明书中所定义。 包含这些化合物的组合物; 还描述了使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US20130261129A1
公开(公告)日：2013-10-03
申请号：US13853394
申请日：2013-03-29
Applicant: ABBVIE INC.
Inventor： Michael D. Meyer , Xueqing Wang , Tao Guo , Robert Wei , Lijuan Jane Wang
IPC: C07D487/08 , C07D451/02
CPC classification number: C07D487/08 , C07D451/02
Abstract: Disclosed herein are chemokine receptor antagonists of formula (I) wherein R1, R2, and R3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.
Abstract translation: 本文公开了式（I）的趋化因子受体拮抗剂，其中R 1，R 2和R 3如说明书中所定义。 包含这些化合物的组合物; 还描述了使用这些化合物和组合物治疗病症和病症的方法。
-
-
-
-
-
-
Search Results
7
records
(took 0.022 seconds)
